On April 16, Southern University of Science and Technology (SUSTech) and the Shenzhen Bay Laboratory signed a memorandum of understanding (MOU) to cooperate and jointly build the Joint Clinical Translational Medicine Research Institute (Institute). The Institute will conduct clinical translational research, focusing on major scientific and technical issues in biomedicine.
SUSTech President Shiyi CHEN, Vice President Dongxiao ZHANG, and Acting Vice President Dongfeng GU were among the senior SUSTech officials who attended the ceremony. They were joined by Shenzhen Bay Laboratory Executive Deputy Director Yundong WU and other officials from the Shenzhen Bay Laboratory.
SUSTech Acting Vice President Dongfeng GU oversaw the signing ceremony, in which Vice President Dongxiao ZHANG and Shenzhen Bay Laboratory Executive Deputy Director Yundong WU signed the MOU on behalf of their respective institutions.
Following the ceremony, Shenzhen Bay Laboratory Executive Deputy Director Yundong WU said in a speech that the Shenzhen Bay Laboratory is committed to serving the major strategic needs of the country. It strives to integrate the superior scientific life and health research resources of the Greater Bay Area into the development of world-class talent pipelines. He looked forward to deep cooperation between both institutions that utilize their unique advantage to explore a diverse range of scientific and technological issues. The Institute will make significant contributions to the development of the biomedical industry in the Greater Bay Area and for the whole country through the construction of scientific research platforms and the cultivation of high-level talents in clinical translation medicine.
SUSTech President Shiyi CHEN echoed the comments of Shenzhen Bay Laboratory Executive Deputy Director Yandong WU, before expanding on SUSTech’s development into medicine. He spoke about the construction of the School of Medicine and its affiliated hospitals, pointing out the importance of multi-party research collaboration. The signing of the MOU will further strengthen the transformation of scientific and technological achievements that serve society. He was also looking forward to the development of world-class talent pipelines and high-impact scientific research platforms. These will bring together world-class research teams that will solve significant scientific health challenges in the life sciences.
SUSTech will take this historic opportunity as part of the dual development drivers of the industrial transformation of the Greater Bay Area and the construction of the pioneering demonstration zone of Shenzhen. It will continue to be an innovative partner in the development of clinical medical translation laboratories that seek to achieve significant breakthroughs in medicine and the life sciences.
